NEONATAL

SURFACTANT (Porcine) – PORACTANT Alpha (Curosurf®)

This document should be read in conjunction with this **DISCLAIMER**

Restricted: Requires neonatologist review within 24 hours of initiation

For all indications, Survanta® is the most cost-effective and hence preferred surfactant preparation within the WNHS NICU, except in extremely preterm infants (≤25 weeks) where Curosurf is to be used or as per the Neonatal Consultant

Presentation	Vials: 120mg/1.5mL 240mg/3mL
Classification	Pulmonary Surfactant – derived from natural porcine lung extract
Indication	Preterm Infants ≤ 25 weeks for treatment and prevention of Respiratory Distress Syndrome Or as per Neonatal Consultant.
Dose	**Rescue treatment** **Initial dose:** 2.5mL/kg (200mg/kg) **Subsequent doses:** 1.25mL/kg (100mg/kg). Up to 2 subsequent doses at 12 hourly intervals may be administered. **Maximum total dose:** 400mg/kg **Prophylaxis** **Initial dose:** 1.25mL-2.5mL/kg 100mg – 200mg/kg) administered within 15 minutes of birth. **Subsequent doses**: 1.25mL (100mg) /kg may be given 6-12 hours after the first dose and then 12 hours later in babies who remain ventilator dependent. **Maximum total dose:** 300-400mg/kg
Monitoring	Continuous oxygen saturation and cardiorespiratory monitoring Evaluate clinical condition before administration and for 30 minutes after each dose.

Guidelines & Resources	WNHS Surfactant Therapy Guideline
Compatible Fluids	Poractant should not be mixed with any other medications or fluids
Preparation	Allow to stand to room temperature for 20 minutes or warm vial in hands. Do not use artificial warming methods. Do not shake vial.
Administration	Do not shake. For intratracheal administration ONLY Survanta is administered via a 5fg end hole catheter shortened to protrude just beyond the end of the ETT, above the carina. Survanta should NOT be instilled into a main stem bronchus. Refer to Surfactant Therapy Guideline
Adverse Reactions	Transient bradycardia, oxygen desaturation, hypotension, endotracheal tube reflux or blockage, pallor, vasoconstriction, hypo/hyper-tension, apnoea, hypo/hyper-carbia
Storage	Refrigerate at 2 to 8^{o}C. Discard open vials 12 hours after opening. Unopened, unused vials of beractant that have been warmed to room temperature can be returned to refrigerated storage within 8 hours for future use. Document on the packaging the date and time that the product was removed from the fridge. Do not warm to room temperature and return to the fridge more than once. Contact Pharmacy for further details.
Notes	For all indications, Survanta® is the most cost-effective and hence preferred surfactant preparation within the WNHS NICU, except in extremely preterm infants (≤25 weeks) where Curosurf is to be used.
References	Truven Health Analytics. Poractant. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2017 [cited 2018 Dec 13]. Available from: https://neofax.micromedexsolutions.com/ South Australia Medication guidelines. Poractant. SA Medication Guidelines [Internet] 2018 [updated Oct 2015; cited Dec 2018]

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	October 2013	Version:	3.0
Last reviewed:	August 2019	Next review date:	August 2022
Endorsed by:	Neonatal Directorate Management Group	Date:	August 2019
Standards Applicable:	NSQHS Standards: 1 Governance 3 Infection Control 4 Medication Safety;		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			